Author Archives: Marisa Wexler MS

Phase 2 Trial of Oral KVD824 in Preventing HAE Attacks to Open

KalVista Pharmaceuticals announced plans to soon begin enrolling patients in KOMPLETE, a Phase 2 clinical trial testing its investigational oral therapy KVD824 in preventing swelling attacks in people with hereditary angioedema (HAE) at sites in Canada, Australia, and the U.K. “Over the past month we have made substantial progress in…

Pharvaris Expanding PHVS416 Trial to US, Launching 2nd Study

RAPIDe-1, a Phase 2 clinical trial testing Pharvaris’ investigational oral therapy PHVS416 as an on-demand treatment for swelling attacks in people with hereditary angioedema (HAE), will expand its enrollment this year to include patients in the U.S. “We are encouraged by positive feedback from clinical sites and look forward…

Interim Data Support Long-term Safety of Orladeyo for HAE Attacks

Treatment with Orladeyo (berotralstat) was generally safe and well-tolerated in people with hereditary angioedema (HAE), according to recently released trial data. The findings from an interim analysis of the open-label APeX-S trial also supported Orladeyo’s ability to reduce the frequency of HAE attacks, ease symptom burden, and improve…

Companies Join to Advance OTL-105, Potential Gene Therapy for HAE

Orchard Therapeutics and the Pharming Group are teaming up to research, develop, manufacture, and — possibly — commercialize a gene therapy for hereditary angioedema (HAE), called OTL-105. “This promising work toward treatment with the potential for durable long-term clinical benefit is encouraging and signifies an ongoing commitment to…

Glenmark Offering New Firazyr Generic in US

The U.S. Food and Drug Administration (FDA) has approved a new generic version of Firazyr (icatibant injection), a medication to treat acute swelling attacks in patients with hereditary angioedema (HAE), Glenmark Pharmaceuticals, announced in a press release. According to the India-based company, the newly approved generic will be…

HAE Patients in US Favored Oral Prophylactic in 2018 Survey

People with hereditary angioedema (HAE) would prefer an oral medication that could prevent their attacks, even when satisfied with their current treatment, a survey of patients in the U.S. reports. The study, “Hereditary angioedema patients would prefer newer-generation oral prophylaxis,” was published in the Journal…